Comparison
BPC-157 is a systemic repair peptide with broad angiogenic and anti-inflammatory properties; GHK-Cu is a copper-binding tripeptide researched primarily for collagen synthesis, wound healing, and skin regeneration.
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Full name | Body Protection Compound-157 | Glycine-Histidine-Lysine + Copper (GHK-Cu) |
| Class | Pentadecapeptide (15 amino acids) | Copper-binding tripeptide (3 amino acids) |
| Mechanism | Angiogenesis, VEGF upregulation, collagen synthesis, nitric oxide modulation, growth factor signalling | Copper chelation and delivery; activates collagen synthesis, anti-inflammatory, antioxidant, promotes stem cell recruitment, activates wound healing gene expression |
| Half-life | ~20–30 minutes | Short; absorbed and distributed rapidly; topical formulations act locally |
| Commonly reported doses | 250–500 mcg per dose SubQ/IM (systemic); oral also researched | 1–3 mg per dose SubQ/IM; topical use also reported (cosmetic applications) |
| Routes | SubQ, IM, oral | SubQ, IM, topical |
| Primary reported use | Systemic healing, gut repair, tendon/ligament, neurological support | Skin regeneration, wound healing, collagen stimulation, anti-aging cosmetic research |
BPC-157 is a systemic peptide with multiple documented signalling pathways — angiogenesis via VEGF, collagen synthesis, nitric oxide pathway modulation, and growth factor receptor modulation. GHK-Cu is a simpler tripeptide that works primarily through copper delivery and the biological activity of the GHK sequence, stimulating collagen and glycosaminoglycan production and activating wound-healing gene networks. The mechanistic breadth of BPC-157 is substantially wider, while GHK-Cu operates with more targeted precision at the level of extracellular matrix remodelling.
In terms of application context, research has investigated BPC-157 for its potential role in acute injury, gut pathology, and systemic inflammatory conditions. GHK-Cu is more commonly researched for wound healing, skin and cosmetic applications — where topical delivery is a clinically relevant option — and anti-aging biological processes. This difference in delivery flexibility means GHK-Cu occupies a distinct niche in cosmetic and dermatological research that BPC-157 does not.
Both peptides have substantial in vitro and animal model research. BPC-157 has notable anecdotal human research data primarily from bodybuilding and recovery communities, with widespread self-reported use. GHK-Cu has a longer scientific history and was first identified as a naturally occurring plasma tripeptide in the 1970s, giving it a more established foundational literature in wound healing and tissue repair science.
BPC-157 promotes angiogenesis through upregulation of VEGF and EGF signalling pathways, supporting new blood vessel formation at sites of tissue damage. It also provides gut mucosal protection and modulates nitric oxide synthesis, contributing to its broad systemic anti-inflammatory profile.
GHK-Cu acts through copper's role in activating lysyl oxidase, the enzyme responsible for collagen crosslinking and extracellular matrix integrity. The GHK sequence independently modulates anti-inflammatory gene expression and demonstrates antioxidant activity. Together, these mechanisms contribute to its well-documented role in wound-healing biology.
BPC-157
GHK-Cu
For BPC-157, commonly reported doses range from 250–500 mcg administered 1–2 times daily via SubQ or IM injection. Oral administration is also researched, particularly for gastrointestinal targeting.
For GHK-Cu, commonly reported doses range from 1–2 mg per day for systemic SubQ or IM use. Topical concentrations vary widely across cosmetic formulations and are not directly comparable to injectable doses.
BPC-157 is most commonly administered via SubQ or IM injection for systemic effects. Oral administration is an alternative route with specific relevance to gastrointestinal research applications, as the peptide may act on gut mucosa directly when taken orally.
GHK-Cu can be administered SubQ or IM for systemic effects, but its topical application in serums and creams is widely studied in cosmetic and dermatological research. This topical delivery option distinguishes GHK-Cu from BPC-157 in terms of accessible research protocols.
Reported side effects in research and anecdotal accounts for BPC-157 include mild nausea and dizziness, particularly at higher doses. It is generally considered well tolerated in the anecdotal literature.
Reported side effects in research and anecdotal accounts for GHK-Cu are minimal. The compound is generally well tolerated. Theoretical copper accumulation risk exists with very high systemic doses. Topical application may cause mild irritation in some individuals, consistent with other cosmetic peptide preparations.
BPC-157 is most commonly explored by individuals researching systemic acute injury recovery, gut repair protocols, and broad anti-inflammatory support. Its systemic reach makes it a common choice in contexts where multiple tissue types or organs are involved.
GHK-Cu is more commonly explored by those focused on skin and cosmetic research, anti-aging biological processes, and wound healing. Its accessibility as a topical compound broadens its reach into cosmetic and dermatology research communities beyond the injectable peptide space.
BPC-157 and GHK-Cu have complementary mechanisms, and combining them is a commonly explored approach in anecdotal and self-research communities. BPC-157 provides systemic angiogenic and anti-inflammatory support, promoting blood vessel formation and broad tissue repair signalling. GHK-Cu contributes copper-mediated collagen synthesis, lysyl oxidase activation, and wound healing gene expression — processes that are distinct from but reinforcing to BPC-157's effects.
No dedicated named stack page exists for this combination on WikiPeptide. Researchers interested in wound healing, skin regeneration, or multi-pathway tissue repair sometimes report using both concurrently. The overlapping anti-inflammatory and collagen-promoting properties are considered additive rather than redundant given the distinct mechanisms involved.
Consider BPC-157 when
Consider GHK-Cu when
For researchers where both systemic repair and collagen synthesis are relevant — such as wound healing following acute injury — both peptides may be appropriate to investigate concurrently given their complementary profiles.
Can GHK-Cu be applied topically where BPC-157 cannot?
Yes. GHK-Cu is widely used in topical cosmetic formulations including serums and creams, where it can act locally on skin and underlying tissue. BPC-157 is typically studied via injection for systemic effects and does not have an established topical research profile comparable to GHK-Cu.
Do BPC-157 and GHK-Cu have overlapping effects?
Both have anti-inflammatory and collagen-promoting properties, but via distinct mechanisms. BPC-157 achieves these effects through angiogenic and growth factor signalling pathways; GHK-Cu through copper-mediated enzyme activation and gene expression modulation. They are considered complementary rather than redundant, which is why combining them is a commonly explored research approach.
Which is better researched?
Both have substantial preclinical literature. GHK has a longer scientific history as a naturally occurring peptide first identified in the 1970s, with extensive foundational research in wound healing biology. BPC-157 has more specific injury and repair model research, along with a large body of anecdotal human data from recovery communities. Neither has robust human clinical trial data at this time.
Peptide Pages